Citadel Advisors
PDSB icon

Citadel Advisors’s PDS Biotechnology PDSB Stock Holding History

Citadel Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
+323,801
New +$344K ﹤0.01% 11224
2025
Q4 		– Sell
-386,430
Closed -$390K – 13714
2025
Q3 		$390K Buy
386,430
+137,405
+55% +$162K ﹤0.01% 9729
2025
Q2 		$331K Buy
+249,025
New +$338K ﹤0.01% 9573
2025
Q1 		– Sell
-220,215
Closed -$313K – 15303
2024
Q4 		$359K Buy
220,215
+105,233
+92% +$279K ﹤0.01% 9294
2024
Q3 		$439K Buy
114,982
+66,272
+136% +$221K ﹤0.01% 8529
2024
Q2 		$143K Sell
48,710
-2,655
-5% -$8.49K ﹤0.01% 10415
2024
Q1 		$203K Sell
51,365
-79,017
-61% -$407K ﹤0.01% 10286
2023
Q4 		$648K Buy
130,382
+34,393
+36% +$171K ﹤0.01% 7548
2023
Q3 		$485K Buy
95,989
+45,138
+89% +$247K ﹤0.01% 8119
2023
Q2 		$256K Sell
50,851
-74,056
-59% -$485K ﹤0.01% 9361
2023
Q1 		$768K Buy
124,907
+97,679
+359% +$799K ﹤0.01% 7376
2022
Q4 		$359K Sell
27,228
-91,795
-77% -$648K ﹤0.01% 8931
2022
Q3 		$353K Buy
119,023
+87,106
+273% +$370K ﹤0.01% 9214
2022
Q2 		$116K Sell
31,917
-55,461
-63% -$264K ﹤0.01% 11265
2022
Q1 		$541K Sell
87,378
-32,704
-27% -$203K ﹤0.01% 9202
2021
Q4 		$973K Sell
120,082
-98,965
-45% -$1.06M ﹤0.01% 8035
2021
Q3 		$3.26M Buy
219,047
+130,633
+148% +$1.63M ﹤0.01% 5178
2021
Q2 		$1.11M Buy
+88,414
New +$690K ﹤0.01% 8093
2019
Q1 		– Sell
-3,020
Closed -$19K – 9715
2018
Q4 		$19K Buy
+3,020
New +$40K ﹤0.01% 8769
2018
Q2 		– Sell
-2,862
Closed -$68K – 9155
2018
Q1 		$68K Buy
+2,862
New +$770K ﹤0.01% 7841

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors's PDSB Position: Q2 2026 in Review

Citadel Advisors opened a new position in PDS Biotechnology (PDSB) in Q2 2026: 323,801 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #11224 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PDSB as recently as Q3 2025.

Citadel Advisors first reported a position in PDSB in Q1 2018 and has held it in 20 quarters since. The position peaked at $3.26M in Q3 2021. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Citadel Advisors held 323,801 shares of PDS Biotechnology worth $285K as of Q2 2026.
  • PDS Biotechnology was a new Citadel Advisors position in Q2 2026.
  • PDS Biotechnology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11224 holding.
  • Citadel Advisors first reported a position in PDS Biotechnology in Q1 2018 and has held it in 20 quarters since.
  • Citadel Advisors's PDS Biotechnology position peaked at $3.26M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.